Chitosan oligosaccharide suppresses tumor progression in a mouse model of colitis-associated colorectal cancer through AMPK activation and suppression of NF-κB and mTOR signaling

Carbohydrate Polymers

Volumn 145, Issue , 2016, Pages 30-36

  Mattaveewong, Tharinee ^a   Wongkrasant, Preedajit ^a   Chanchai, Sumalee ^a   Pichyangkura, Rath ^b   Chatsudthipong, Varanuj ^a,c,d   Muanprasat, Chatchai ^a,c,d  

^a Mahidol University ^*  (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c Thailand Center of Excellence for Life Sciences   (Thailand)

^d THAILAND CENTER OF EXCELLENCE IN PHYSICS   (Thailand)

Author keywords

AMP activated protein kinase; Chemoprevention; Chitosan oligosaccharide; Colorectal cancer

Indexed keywords

ANTIBIOTICS; CHEMICAL ACTIVATION; CHITIN; CHITOSAN; ENZYME ACTIVITY; MAMMALS; OLIGOSACCHARIDES; PROTEINS; TUMORS;

AMP-ACTIVATED PROTEIN KINASE; CHEMOPREVENTION; CHITOSAN OLIGOSACCHARIDE; COLORECTAL CANCER; COLORECTAL CANCERS (CRC); INFLAMMATORY RESPONSE; ORAL ADMINISTRATION; TUMOR PROGRESSIONS;

DISEASES;

ANTINEOPLASTIC AGENT; CCND1 PROTEIN, MOUSE; CHITOSAN; CYCLIN D1; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MMP9 PROTEIN, MOUSE; MTOR PROTEIN, MOUSE; OLIGOSACCHARIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; C57BL MOUSE; CHEMISTRY; COLITIS; COLON; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTICARCINOGENIC AGENTS; CHITOSAN; COLITIS; COLON; COLORECTAL NEOPLASMS; CYCLIN D1; DISEASE MODELS, ANIMAL; MALE; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; NF-KAPPA B; OLIGOSACCHARIDES; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 84961745266     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2016.02.077     Document Type: Article

References (31)

1. Y. Baba, K. Nosho, K. Shima, J.A. Meyerhardt, A.T. Chan, J.A. Engelman, and S. Ogino Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer British Journal of Cancer 103 7 2010 1025 1033
2. E. Bess, B. Fisslthaler, T. Fromel, and I. Fleming Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells PLoS One 6 6 2011 e20848
3. S. Chen, X. Zhu, X. Lai, T. Xiao, A. Wen, and J. Zhang Combined cancer therapy with non-conventional drugs: all roads lead to AMPK Mini-Reviews in Medicinal Chemistry 14 8 2014 642 654
4. Y. Choudhury, Z. Yang, I. Ahmad, C. Nixon, I.P. Salt, and H.Y. Leung AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer Oncoscience 1 6 2014 446 456
5. F.V. Din, A. Valanciute, V.P. Houde, D. Zibrova, K.A. Green, K. Sakamoto, and M.G. Dunlop Aspirin inhibits mTOR signaling activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells Gastroenterology 142 7 2012 1504 1515 e1503
6. A.M. Fajardo, and G.A. Piazza Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention American Journal of Physiology-Gastrointestinal and Liver Physiology 309 2 2015 G59 70
7. W.J. Faller, T.J. Jackson, J.R. Knight, R.A. Ridgway, T. Jamieson, S.A. Karim, and O.J. Sansom mTORC1-mediated translational elongation limits intestinal tumour initiation and growth Nature 517 7535 2015 497 500
8. X. Garcia-Albeniz, and A.T. Chan Aspirin for the prevention of colorectal cancer Best Practice & Research Clinical Gastroenterology 25 4-5 2011 461 472
9. S.M. Hadad, D.G. Hardie, V. Appleyard, and A.M. Thompson Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle Clinical and Translational Oncology 16 8 2014 746 752
10. S.A. Hawley, M.D. Fullerton, F.A. Ross, J.D. Schertzer, C. Chevtzoff, K.J. Walker, and D.G. Hardie The ancient drug salicylate directly activates AMP-activated protein kinase Science 336 6083 2012 918 922
11. X. Huang, S. Wullschleger, N. Shpiro, V.A. McGuire, K. Sakamoto, Y.L. Woods, and D.R. Alessi Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice Biochemical Journal 412 2 2008 211 221
12. S.J. Koh, J.M. Kim, I.K. Kim, S.H. Ko, and J.S. Kim Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer Journal of Gastroenterology and Hepatology 29 3 2014 502 510
13. M.A. Lea, J. Pourat, R. Patel, and C. desBordes Growth inhibition of colon cancer cells by compounds affecting AMPK activity World Journal of Gastrointestinal Oncology 6 7 2014 244 252
14. W. Li, B. Hua, S.M. Saud, H. Lin, W. Hou, M.S. Matter, and M.R. Young Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice Molecular Carcinogenesis 54 10 2015 1096 1109
15. Y. Li, H. Liu, Q.S. Xu, Y.G. Du, and J. Xu Chitosan oligosaccharides block LPS-induced O-GlcNAcylation of NF-kappaB and endothelial inflammatory response Carbohydrate Polymers 99 2014 568 578
16. X. Liu, M. Jakubowski, and J.L. Hunt KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis American Journal of Clinical Pathology 135 2 2011 245 252
17. C.N. Mhurchu, S.D. Poppitt, A.T. McGill, F.E. Leahy, D.A. Bennett, R.B. Lin, and A. Rodgers The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults International Journal of Obesity and Related Metabolic Disorders 28 9 2004 1149 1156
18. C. Muanprasat, P. Wongkrasant, S. Satitsri, A. Moonwiriyakit, P. Pongkorpsakol, T. Mattaveewong, and V. Chatsudthipong Activation of AMPK by chitosan oligosaccharide in intestinal epithelial cells: mechanism of action and potential applications in intestinal disorders Biochemical Pharmacology 96 3 2015 225 236
19. S.Y. Park, C.H. Jung, B. Song, O.J. Park, and Y.M. Kim Pro-apoptotic and migration-suppressing potential of EGCG, and the involvement of AMPK in the p53-mediated modulation of VEGF and MMP-9 expression Oncology Letters 6 5 2013 1346 1350
20. G.S. Ranger Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors Anticancer Research 34 11 2014 6277 6282
21. C.V. Rao Nitric oxide signaling in colon cancer chemoprevention Mutation Research 555 1-2 2004 107 119
22. H. Raskov, H.C. Pommergaard, J. Burcharth, and J. Rosenberg Colorectal carcinogenesis - update and perspectives World Journal of Gastroenterology 20 48 2014 18151 18164
23. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited The FASEB Journal 22 3 2008 659 661
24. D. Serrano, M. Lazzeroni, and B. Bonanni Cancer chemoprevention: much has been done, but there is still much to do. State of the art and possible new approaches Molecular Oncology 9 5 2015 1008 1017
25. R.J. Shaw LKB1 and AMP-activated protein kinase control of mTOR signalling and growth Acta Physiologica (Oxford) 196 1 2009 65 80
26. M. Takahashi, and K. Wakabayashi Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents Cancer Science 95 6 2004 475 480
27. A.G. Vaiopoulos, K. Athanasoula, and A.G. Papavassiliou NF-kappaB in colorectal cancer Journal of Molecular Medicine (Berlin) 91 9 2013 1029 1037
28. W. Wang, and K.L. Guan AMP-activated protein kinase and cancer Acta Physiologica (Oxford) 196 1 2009 55 63
29. M. Yousef, R. Pichyangkura, S. Soodvilai, V. Chatsudthipong, and C. Muanprasat Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action Pharmacological Research 66 1 2012 66 79
30. G. Zadra, J.L. Batista, and M. Loda Dissecting the dual role of AMPK in cancer: from experimental to human studies Molecular Cancer Research 13 7 2015 1059 1072
31. E. Zulato, F. Bergamo, A. De Paoli, G. Griguolo, G. Esposito, G.L. De Salvo, and V. Zagonel Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab British Journal of Cancer 111 1 2014 25 32